This is a working overview of body composition, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-10 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
== History == Following the discovery in 1952 that the tuberculosis drug iproniazid elevated the mood of people taking it, and the subsequent discovery that the effect was likely due to inhibition of monoamine oxidase (MAO) and elevation of monoamine neurotransmitters in the brain, many people and companies started trying to discover monoamine oxidase inhibitors (MAOIs) to use as antidepressants. Deprenyl, the racemic form of selegiline, was synthesized and discovered by Zoltan Ecseri at the Chinoin Pharmaceutical Company (part of Sanofi since 1993) in Budapest, Hungary. Chinoin received a patent on the drug in 1962 and the compound was first published in the scientific literature in English in 1965. Chinoin researchers had been studying substituted amphetamines since 1960, and decided to try synthesizing amphetamines that acted as MAOIs. It had been known that methamphetamine was a reversible inhibitor of MAO. Deprenyl, also known as N-propargyl-N-methylamphetamine, is closely related to and inspired by pargyline (N-propargyl-N-methylbenzylamine), another MAOI that had been synthesized earlier. Deprenyl was initially referred to by the chemical name phenylisopropylmethylpropinylamine and the developmental code name E-250. Work on the biology and effects of E-250 in animals and humans was conducted by a group led by József Knoll at Semmelweis University, which was also in Budapest. Deprenyl is a racemic compound (a mixture of two isomers called enantiomers).
17 January – A study in Nature finds that the Greenland ice sheet is melting 20% faster than previously estimated, due to the effects of calving-front retreat. The loss of 30m tonnes of ice an hour is "sufficient to affect ocean circulation and the distribution of heat energy around the globe." 18 January NASA reports the end of the Ingenuity helicopter's operation, after 72 successful flights on Mars, due to a broken rotor blade. A potential candidate for the first known radio pulsar-black hole binary is reported by astronomers. The heavier of the two lies in the "mass gap" between neutron stars and black holes. The pair are located in the globular cluster NGC 1851. Two insect-like robots, a mini-bug and a water strider, are reported as being the smallest, lightest, and fastest fully-functional micro-robots ever created. Bottom trawling is found to release 340 million tonnes of carbon dioxide (CO2) into the atmosphere each year, nearly 1 percent of all global CO2 emissions in addition to acidifying oceans. 19 January – Japan becomes the fifth country to achieve a soft landing on the Moon, with its SLIM mission. 21 January – Biologists report the discovery of "obelisks", a new class of viroid-like elements, and "oblins", their related group of proteins, in the human microbiome. 23 January – A viable and sustainable approach for gold recovery from e-waste is demonstrated.
This was his best result in Miami since reaching the final in 2018. Zverev began his 2024 clay season seeded fifth at the Monte-Carlo Masters, receiving a bye into the second round and defeating Sebastian Ofner before losing to eventual champion Stefanos Tsitsipas in the third round. As the top seed at the BMW Open, Zverev received a bye into the second round and beat Jurij Rodionov before being upset by world No. 106 Cristian Garín in the quarterfinals. Seeded fourth in Madrid, Zverev reached the fourth round, beating Borna Ćorić and Denis Shapovalov before being upset by 21st seed Francisco Cerúndolo. Seeded third in Rome, Zverev won his sixth Masters title, defeating Aleksandar Vukic, Nuno Borges, Taylor Fritz, Alejandro Tabilo, and Nicolás Jarry in the final. This was his best result in Rome since winning his first Masters 1000 title at the 2017 Italian Open, and his first Masters title since 2021. At the French Open, Zverev contested Rafael Nadal's final match at the French Open, defeating the 14-time champion in straight sets to record Nadal's fourth ever defeat at the event. He went on to reach the semifinals, winning over David Goffin, Tallon Griekspoor, Holger Rune, and Alex de Minaur. He then defeated two-time finalist Casper Ruud to reach his first Major final since the 2020 US Open and his first on clay. In the deciding set of the final match, Alcaraz hit a second serve which was called out by the line judges. However, the chair umpire overruled the call, declaring the ball in.
You see, we were having negotiations with these lunatics, and it was my opinion that they [the Iranians] were going to attack first." On April 2, US president Trump stated he does not "care" about Iran's stock of highly enriched uranium (HEU) as it is underground, contradicting a key rationale he brought up when starting the war. In fact, Iran's HEU stock is now assessed as a more risky scenario than before the war began, as it would leave Iran significantly closer to the capability of making nuclear bombs than the proposed settlement being negotiated in Geneva two days before the war began. Iran's development of HEU stockpile itself is the consequence of Trump's decision in 2018 to withdraw from a multilateral nuclear deal. Another reason given by the Trump administration for initiating the war was the desire to seize Iran's oil and gas resources. According to the political scientist Vali Nasr, Trump aspired to become the American president who finally resolved the Iran problem.
Genetic or syndromic gingival enlargement, such as Zimmermann-Laband or Ramon syndrome, presents as firm, fibrotic, and persistent nodular gingival overgrowth that usually begins around tooth eruption. Systemic or hormonal causes, including pregnancy, hormonal imbalance, leukemia, granulomatosis with polyangiitis (strawberry gingivitis), and vitamin C deficiency, can also result in gingival enlargement. In rare cases, gingival enlargement may be neoplastic, such as in squamous cell carcinoma or fibroma. Clinically, gingival enlargement often obscures the CEJ, and the gingival margin appears coronally positioned. Unlike CAL, gingival enlargement is often reversible or manageable once the underlying cause is addressed, though surgical correction may be required in fibrotic or genetic cases.
Sources: en.wikipedia.org
== Prognosis == Mild and moderate cerebral hypoxia may result in seizures and long-term memory impairment. The outcome of severe cerebral hypoxia will depend on the success of damage control, the amount of brain tissue deprived of oxygen, and the speed with which oxygen is restored. If cerebral hypoxia is localized to a specific part of the brain, brain damage will be localized to that region. A general consequence may be epilepsy. The long-term effects will depend on the purpose of that portion of the brain. Damage to the Broca's area and the Wernicke's area of the brain (left side) typically causes problems with speech and language. Damage to the right side of the brain may interfere with the ability to express emotions or interpret what one sees. Damage on either side can cause paralysis of the opposite side of the body. The effects of certain kinds of severe generalized hypoxias may take time to develop. For example, the long-term effects of serious carbon monoxide poisoning usually may take several weeks to appear. Recent research suggests this may be due to an autoimmune response caused by carbon monoxide-induced changes in the myelin sheath surrounding neurons. If hypoxia results in coma, the length of unconsciousness is often indicative of long-term damage. In some cases coma can allow the brain to heal and regenerate, but, in general, the longer a coma, the greater the likelihood that the person will remain in a vegetative state until death. Even if the patient wakes up, brain damage is likely to be significant enough to prevent a return to normal functioning.
1993/2957) A10 Trunk Road (Wadesmill, High Cross and Colliers End Bypass and Slip Road) Order 1993 (S.I. 1993/2963) A10 Trunk Road (North of Ware to South of Puckeridge) (Detrunking) Order 1993 (S.I. 1993/2964) Education (School Inspection) (Wales) (No. 2) (Amendment) Regulations 1993 (S.I. 1993/2968) Scottish College of Textiles (Scotland) Order of Council 1993 (S.I. 1993/2969) Civil Aviation (Route Charges for Navigation Services) (Amendment) Regulations 1993 (S.I. 1993/2970) Hereford and Worcester and West Midlands (County Boundaries) Order 1993 (S.I. 1993/2971) National Health Service (Service Committees and Tribunal) Amendment Regulations 1993 (S.I. 1993/2972) Education (School Inspection) (No. 2) (Amendment) Regulations 1993 (S.I. 1993/2973) Port of Bristol Harbour Revision Order 1993 (S.I. 1993/2974) Civil Aviation (Joint Financing) (Fifth Amendment) Regulations 1993 (S.I. 1993/2975) Gipsy Encampments (East Yorkshire Borough of Beverley) Order 1993 (S.I. 1993/2980)
== Early life and education == Kendall was born in South Norwalk, Connecticut in 1886. He attended Columbia University, earning a Bachelor of Science degree in 1908, a Master of Science degree in Chemistry in 1909, and a Ph.D. in Chemistry in 1910.
Ypadú or ypadu (also known as mambé) is an unrefined, unconcentrated powder made from toasted coca leaves and the ash of various other plants. It is traditionally prepared and consumed by indigenous tribes in the Northwest Amazon. Like coca teas consumed in Peru to adapt to sickness induced by high elevation, it has a long ethnobotanical history and cultural associations.
Sources: en.wikipedia.org
The CompTox Chemicals Dashboard is a freely accessible online database created and maintained by the U.S. Environmental Protection Agency (EPA). The database provides access to multiple types of data including physicochemical properties, environmental fate and transport, exposure, usage, in vivo toxicity, and in vitro bioassay. EPA and other scientists use the data and models contained within the dashboard to help identify chemicals that require further testing and reduce the use of animals in chemical testing. The Dashboard is also used to provide public access to information from EPA Action Plans, e.g. around perfluorinated alkylated substances. Originally titled the Chemistry Dashboard, the first version was released in 2016. The latest release of the database (version 3.0.5) contains manually curated data for over 875,000 chemicals and incorporates the latest data generated from the EPA's Toxicity Forecaster (ToxCast) high-throughput screening program. The Chemicals Dashboard incorporates data from several previous EPA databases into one package including the ToxCast Dashboard, the Endocrine Disruption Screening Program (EDSP) Dashboard and the Chemical and Products Database (CPDat).
== MrBayes software == MrBayes is a free software tool that performs Bayesian inference of phylogeny. It was originally written by John P. Huelsenbeck and Frederik Ronquist in 2001. As Bayesian methods increased in popularity, MrBayes became one of the software of choice for many molecular phylogeneticists. It is offered for Macintosh, Windows, and UNIX operating systems and it has a command-line interface. The program uses the standard MCMC algorithm as well as the Metropolis coupled MCMC variant. MrBayes reads aligned matrices of sequences (DNA or amino acids) in the standard NEXUS format. MrBayes uses MCMC to approximate the posterior probabilities of trees. The user can change assumptions of the substitution model, priors and the details of the MC³ analysis. It also allows the user to remove and add taxa and characters to the analysis. The program includes, among several nucleotide models, the most standard model of DNA substitution, the 4x4 also called JC69, which assumes that changes across nucleotides occur with equal probability. It also implements a number of 20x20 models of amino acid substitution, and codon models of DNA substitution. It offers different methods for relaxing the assumption of equal substitutions rates across nucleotide sites. MrBayes is also able to infer ancestral states accommodating uncertainty to the phylogenetic tree and model parameters. MrBayes 3 was a completely reorganized and restructured version of the original MrBayes. The main novelty was the ability of the software to accommodate heterogeneity of data sets.
== Overview == The aquatic inorganic carbon system is composed of the various ionic, dissolved, solid, and/or gaseous forms of carbon dioxide in water. These species include dissolved carbon dioxide, carbonic acid, bicarbonate anion, carbonate anion, calcium carbonate, magnesium carbonate, and others. The relative amounts of each species in a body of water depends on physical variables including temperature and salinity, as well as chemical variables like pH and gas partial pressure. Variables like alkalinity and dissolved (or total) inorganic carbon further define a mass and charge balance that constrains the total state of the system. Given any two of the four central inorganic carbon system parameters (pH, alkalinity, dissolved inorganic carbon, partial pressure of carbon dioxide) the remainder may be derived by solving a system of equations that adhere to the principles of chemical thermodynamics. For most of the 20th century, chemical equilibria in marine and freshwater systems were calculated according to various conventions, which led to discrepancies among laboratories' calculations and limited scientific reproducibility. Since 1998, a family of software programs called CO2SYS has been widely used. This software calculate chemical equilibria for aquatic inorganic carbon species and parameters. Their core function is to use any two of the four central inorganic carbon system parameters (pH, alkalinity, dissolved inorganic carbon, and partial pressure of carbon dioxide) to calculate various chemical properties of the system.
== Predicted properties == According to the periodic law, dubnium should belong to group 5, with vanadium, niobium, and tantalum. Several studies have investigated the properties of element 105 and found that they generally agreed with the predictions of the periodic law. Significant deviations may nevertheless occur, due to relativistic effects, which dramatically change physical properties on both atomic and macroscopic scales. These properties have remained challenging to measure for several reasons: the difficulties of production of superheavy atoms, the low rates of production, which only allows for microscopic scales, requirements for a radiochemistry laboratory to test the atoms, short half-lives of those atoms, and the presence of many unwanted activities apart from those of synthesis of superheavy atoms. So far, studies have only been performed on single atoms.
=== Sequence entropy === In bioinformatics, a sequence entropy, also known as sequence complexity or information profile, is a numerical sequence providing a quantitative measure of the local complexity of a DNA sequence, independently of the direction of processing. The manipulations of the information profiles enable the analysis of the sequences using alignment-free techniques, such as for example in motif and rearrangements detection.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.